Insider · CIK 0001194020
Timothy C Dec
Files at SUPN (SUPERNUS PHARMACEUTICALS, INC.). First filing Aug 26, 2025, latest Aug 26, 2025.
In brief
Timothy C Dec files SEC Form 4 as CFO and president at SUPN (SUPERNUS PHARMACEUTICALS, INC.). Since Aug 26, 2025, Timothy C Dec has reported 0 open-market buys worth $0 and 1 open-market sell worth $524k, the latest filed on Aug 26, 2025.
A track record needs three past buys with six months of prices behind them; Timothy C Dec has 0, so none is measured yet.
The newest scored trade: sold $524k of SUPN on Aug 22, 2025, filed Aug 26, 2025, scored 75 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SUPN: SUPERNUS PHARMACEUTICALS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 75Notable | SUPERNUS PHARMACEUTICALS, INC. | $524k 11,780 shares | -90% | +50% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | 11,780 0.02% of outstanding | $524k | Aug 22, 2025 | none |
Transactions
The newest 50 of 56 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,250 | $0.00 | $0 | 9,733 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -604 | $46.57 | $28k | 9,129 | Aug 14, 2026 |
| Aug 12, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,250 | $0.00 | $0 | 0 | Aug 14, 2026 |
| Jul 29, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,250 | $0.00 | $0 | 1,250 | Jul 31, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +3,000 | $0.00 | $0 | 8,115 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,433 | $54.73 | $78k | 6,682 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +3,000 | $0.00 | $0 | 9,682 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,450 | $54.73 | $79k | 8,232 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -3,000 | $0.00 | $0 | 0 | Mar 10, 2026 |
| Mar 6, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -3,000 | $0.00 | $0 | 0 | Mar 10, 2026 |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Mar 3, 2026 |
| Feb 28, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Mar 3, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 6,394 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,279 | $50.69 | $65k | 5,115 | Feb 26, 2026 |
| Feb 25, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -2,500 | $0.00 | $0 | 2,500 | Feb 26, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +1,125 | $0.00 | $0 | 2,763 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -603 | $51.35 | $31k | 2,160 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +500 | $0.00 | $0 | 2,660 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -242 | $50.86 | $12k | 2,418 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +3,000 | $0.00 | $0 | 5,418 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,524 | $50.86 | $78k | 3,894 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -1,125 | $0.00 | $0 | 3,375 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -500 | $0.00 | $0 | 0 | Feb 25, 2026 |
| Feb 24, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -3,000 | $0.00 | $0 | 6,000 | Feb 25, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +17,500 | $0.00 | $0 | 17,500 | Feb 20, 2026 |
| Feb 18, 2026 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +3,000 | $0.00 | $0 | 3,000 | Feb 20, 2026 |
| Aug 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | SOpen-market sale Common Stock | -11,780 | $44.49 | $524k | 1,246 | Aug 26, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +2,000 | $0.00 | $0 | 12,898 | Mar 11, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,062 | $32.06 | $34k | 11,836 | Mar 11, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Common Stock | +1,800 | $0.00 | $0 | 13,636 | Mar 11, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -955 | $32.06 | $31k | 12,681 | Mar 11, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -2,000 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 10, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | MOption exercise Performance Share Unitderivative | -1,800 | $0.00 | $0 | 0 | Mar 11, 2025 |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -276 | $33.05 | $9,122 | 13,815 | Mar 5, 2025 |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,587 | $33.05 | $52k | 12,228 | Mar 5, 2025 |
| Mar 5, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,330 | $33.05 | $44k | 10,898 | Mar 5, 2025 |
| Feb 28, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +2,000 | $0.00 | $0 | 2,000 | Mar 4, 2025 |
| Feb 28, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Performance Share Unitderivative | +1,800 | $0.00 | $0 | 1,800 | Mar 4, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +500 | $0.00 | $0 | 8,591 | Feb 24, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +3,000 | $0.00 | $0 | 11,591 | Feb 24, 2025 |
| Feb 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 14,091 | Feb 24, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -500 | $0.00 | $0 | 500 | Feb 24, 2025 |
| Feb 22, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -3,000 | $0.00 | $0 | 9,000 | Feb 24, 2025 |
| Feb 23, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -2,500 | $0.00 | $0 | 5,000 | Feb 24, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Employee Stock Option (Right to Buy)derivative | +40,000 | $0.00 | $0 | 40,000 | Feb 21, 2025 |
| Feb 19, 2025 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Restricted Stock Unitderivative | +4,500 | $0.00 | $0 | 4,500 | Feb 21, 2025 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 8,504 | Feb 27, 2024 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | FTax withholding Common Stock | -1,314 | $29.06 | $38k | 7,190 | Feb 27, 2024 |
| Feb 23, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | DDisposition to issuer Restricted Stock Unitderivative | -2,500 | $0.00 | $0 | 7,500 | Feb 27, 2024 |
| Feb 22, 2024 | SUPN SUPERNUS PHARMACEUTICALS, INC. | AGrant or award Common Stock | +500 | $0.00 | $0 | 6,004 | Feb 26, 2024 |
Questions about Timothy C Dec
Answered from the filings on this page, as of the latest one.
Is Timothy C Dec buying or selling?
Not in the last 12 months. Timothy C Dec's latest open-market trade on SEC Form 4 was sold $524k of SUPN on Aug 22, 2025.
How did Timothy C Dec's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Timothy C Dec has 0.
Where does Timothy C Dec file Form 4?
Timothy C Dec has filed Form 4 at SUPN (SUPERNUS PHARMACEUTICALS, INC.) as Senior Vice-President & CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.